New And Special Drugs
-
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
-
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
-
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
-
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-
Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
-
Exdensur (Depemokimab) – Eosinophilic Asthma | HongKong DengYue Medicine
-
Zometa (Zoledronic Acid) – HCM | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
China API Industry Overview: Key Strength Areas, Supply Chain Capabilities, and Global Market Position
Over the past two decades, the China API industry has evolved into a foundational pillar of the global pharmaceutical ecosystem. 🌏 HongKong DengYue Medicine continues
How to Find Generic Drug Versions in China: A Practical Guide to Verification and Availability
In the global healthcare system, generic drugs have become an important way to reduce treatment costs and improve access to medicines. In China, the continuous
What Are Degrader-Antibody Conjugates (DACs)? Next-Generation ADC Technology and the Global Pipeline Landscape
The excitement surrounding antibody-drug conjugates (ADCs) has not yet faded, but a new frontier is already capturing the attention of global pharmaceutical giants. 🔥 Recently,
The World’s Second CFB Inhibitor Lanoracopan Approved by NMPA: China-Developed PNH Therapy Marks a Breakthrough
On June 11, China’s National Medical Products Administration (NMPA) officially approved Wuhan Createrna Science and Technology’s self-developed lanoracopan hydrochloride tablets (Yishining®) for the treatment of
Gumokimab Approved for Plaque Psoriasis in China: The IL-17A Therapy Landscape Continues to Evolve
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name Qiyoukang®), received approval from China’s National Medical Products Administration (NMPA)
10 Key Questions Cancer Patients Ask: From Survival Rates to Treatment Options
Cancer treatment is often a long and uncertain journey. Global pharmaceutical distributor DengYueMed has organized the 10 key questions cancer patients ask to help patients
Mazdutide vs Semaglutide: ADA 2026 DREAMS-3 Trial Shows Superior Efficacy in Type 2 Diabetes With Obesity
On June 8, Innovent Biologics announced the results of the Phase III DREAMS-3 head-to-head trial of Mazdutide vs Semaglutide at the 2026 American Diabetes Association
New Hemophilia Drug Approved in China: Bemiltenase Alfa Becomes World’s First Factor X Activator
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (STSP-0601), a Class 1 innovative biologic developed by BioJeTay, a subsidiary of Shutaishen
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
